
First Patient Dosed in Immunotherapy Combo Trial of Yervoy, Evofosfamide in Solid Tumors
The first patient has been dosed in a Phase 1 clinical trial evaluating the immunotherapy combination of Threshold Pharmaceuticals‘ evofosfamide (TH-302) plus Bristol-Myers Squibb‘s Yervoy (ipilimumab) for the treatment of patients with advanced solid malignancies.
The single-arm, open-label Phase 1 trial (NCT03098160), being conducted at the University of Texas MD Anderson Cancer Center in Houston, will enroll up to 69 patients with confirmed metastatic or locally advanced prostate cancer, metastatic pancreatic cancer, melanoma, or human papillomavirus (HPV) negative squamous cell carcinoma of the head and neck.
Eligible participants are those who have failed to respond to standard therapy, progressed despite standard therapy, or those for whom standard therapy does not offer the potential for increased survival.
Link para a notícia: Immuno-Oncology News







